Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Operations (2021 - 2025)

Aligos Therapeutics' Cash from Operations history spans 5 years, with the latest figure at 21745000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 18.16% year-over-year to 21745000.0; the TTM value through Dec 2025 reached 82503000.0, down 2.18%, while the annual FY2025 figure was 82503000.0, 2.18% down from the prior year.
  • Cash from Operations reached 21745000.0 in Q4 2025 per ALGS's latest filing, up from 24345000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 13616000.0 in Q2 2023 to a low of 37480000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 21864700.0, with a median of 21327000.0 recorded in 2025.
  • Peak YoY movement for Cash from Operations: soared 55.22% in 2022, then tumbled 43.16% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 37480000.0 in 2021, then skyrocketed by 55.22% to 16783000.0 in 2022, then plummeted by 35.01% to 22658000.0 in 2023, then grew by 18.78% to 18403000.0 in 2024, then fell by 18.16% to 21745000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Cash from Operations are 21745000.0 (Q4 2025), 24345000.0 (Q3 2025), and 15504000.0 (Q2 2025).